Last reviewed · How we verify
ThisCART7 cells
At a glance
| Generic name | ThisCART7 cells |
|---|---|
| Sponsor | Fundamenta Therapeutics, Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ThisCART7 cells CI brief — competitive landscape report
- ThisCART7 cells updates RSS · CI watch RSS
- Fundamenta Therapeutics, Ltd. portfolio CI